Drug Profile
Research programme: ghrelin antagonists - Ocera Therapeutics
Alternative Names: TZP-301Latest Information Update: 14 Dec 2017
Price :
$50
*
At a glance
- Originator Tranzyme Pharma
- Developer Ocera Therapeutics
- Class
- Mechanism of Action Ghrelin antagonists; Ghrelin inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Metabolic syndrome; Obesity
Most Recent Events
- 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt
- 04 Sep 2013 No development reported - Preclinical for Metabolic syndrome in USA (unspecified route)
- 04 Sep 2013 No development reported - Preclinical for Obesity in USA (unspecified route)